Nicholas Warren PhD retweeted
Honored that my first meeting in D.C. was with the Children’s Hospital Alliance of Tennessee. Their commitment to caring for our state’s children is remarkable, and I look forward to supporting their mission in Congress.
Nicholas Warren PhD retweeted
A recent @CCR_AACR perspective discussed how to improve collection and analysis of #OverallSurvival data in oncology clinical trials. @WarrenNJH breaks down the key lessons on the #AACRBlog: bit.ly/3Ws9lTy
#AACRSciencePolicy
Nicholas Warren PhD retweeted
A recent @CCR_AACR perspective discussed how to improve collection and analysis of #OverallSurvival data in oncology clinical trials. A new Cancer Research Catalyst blog by @WarrenNJH breaks down the key lessons: bit.ly/4daGfP7
#AACRSciencePolicy
Nicholas Warren PhD retweeted
⬇️ Starting now!
@US_FDA Center for Tobacco Products’ Prioroties to Reduce Tobacco Use and Support the #Cancer Moonshot
Room 5, second floor.
#AACR24 @AACR @bentollphd – at San Diego, CA
Please join us this morning @AACR with @FDATobacco Director Brian King I’ll be on the panel @christine_lovly @muschollings #AACR24
Nicholas Warren PhD retweeted
Ruixiao Lu of the American Statistical Association, @AmStatNews, moderated a panel discussion on @FDAOncology's Project Endpoint and overall survival at #AACR24 today. #AACRSciencePolicy
Nicholas Warren PhD retweeted
.@DrRoyHerbstYale will moderate an #AACRSciencePolicy session to showcase the reignited #CancerMoonshot. @NCIDirector Kimryn Rathmell and other panelists will discuss how we can achieve meaningful progress to “end cancer as we know it.” bit.ly/3xoa6Eg #AACRSciencePolicy
Nicholas Warren PhD retweeted
Please join these experts & me at #AACR24 for an engaging discussion on how to define benefit/risk with targeted oncology therapies for patients with cancer. See you in San Diego! abstractsonline.com/pp8/#!/2…
@OncoAlert #CRCSM @AACR
Nicholas Warren PhD retweeted
A proposed @FDA rule would classify laboratory-developed tests as medical devices subject to regulatory oversight. @DrTonyLetai will moderate an #AACR24 discussion of the benefits and challenges of this new regulatory framework. bit.ly/4cDDI0I
#AACRSciencePolicy
Nicholas Warren PhD retweeted
#MCED assays are a promising tool for #earlydetection of cancer, but questions remain about risk assessment in multi-cancer settings and use in clinical practice. Lauren Leiman will moderate an #AACR24 discussion of the future of MCED. bit.ly/49f7i9S
#AACRSciencePoilcy
Nicholas Warren PhD retweeted
Today is the AACR Early-Career National Day of Action, and we're calling on early-career scientists, trainees, students, and all who support them to contact members of Congress and ask them to prioritize @NIH funding. Take action: AACR.org/AACRECHD24 #AACRontheHill #FundNIH
Nicholas Warren PhD retweeted
Thanks to everyone who participated in today's @US_FDA_Oncology-AACR Workshop on Optimizing Dosages for Oncology Drug Products. Session recordings and slides will be posted to the AACR website by Thursday, February 22. Learn more: bit.ly/498SYAp #AACRSciencePolicy
Nicholas Warren PhD retweeted
AACR President-Elect Patricia M. LoRusso moderated a panel discussion on lessons learned and next steps to close out the @US_FDA-AACR dosage optimization workshop. We thank the moderators, speakers, and panelists, for their contributions to this vital event. #AACRSciencePolicy
Nicholas Warren PhD retweeted
AACR President-Elect Patricia M. LoRusso and @FDAOncology’s Marc Theoret opened today's FDA-AACR Workshop on Optimizing Dosages for Oncology Drug Products. Participants will share examples of and rationales behind effective dosage optimization strategies. #AACRSciencePolicy
Nicholas Warren PhD retweeted
AACR President-Elect and #AACRFellows Patricia M. LoRusso, DO, PhD (hc), was quoted in this AP story about reducing doses of chemotherapy drugs to minimize side effects. Dr. LoRusso will chair an AACR-@US_FDA workshop on this topic Feb 15-16. Learn more:
aacr.org/professionals/polic…
As cancer treatment advances, patients and doctors push back against drugs' harsh side effects apnews.com/article/cancer-tr…
Nicholas Warren PhD retweeted
AACR and @US_FDA will host a workshop on ways to improve dosage optimization for oncology drugs. Learn more from cochairs Patricia M. LoRusso and Stacy Shord on the #AACRBlog: bit.ly/49r0GW6 #AACRSciencePolicy @YaleCancer
Nicholas Warren PhD retweeted
AACR President-Elect Patricia LoRusso joins Stacy Shord and Jiang Liu of @US_FDA to chair a workshop on dosage optimization for oncology drug products. Join us February 15-16, in Washington, DC, or on livestream. Learn more:
bit.ly/3O5VSNW
#AACRSciencePolicy
Nicholas Warren PhD retweeted
The AACR joins with other organizations in calling on @WhiteHouse to finalize a ban on menthol cigarettes and flavored cigars. These regulations are needed to achieve the goals of the Cancer Moonshot. Learn more: bit.ly/3Sk9SWJ
Nicholas Warren PhD retweeted
The fourth edition of the FDA-AACR Oncology Educational Fellowship program launched on Friday with a virtual meeting. The 21 early-career researchers and physician-scientists in this year’s class will learn more about drug development and the regulatory process from @FDAOncology.
Nicholas Warren PhD retweeted
In the latest Policy Matters, @WarrenNJH of the @AACR writes about efforts to make clinical trials that reflect the diversity of the people in cancer treatment. bit.ly/3PEeCnF
Nicholas Warren PhD retweeted
We appreciate @CNN's coverage of our #CancerProgressReport 2023. Learn more at
cancerprogressreport.aacr.or…
@JacqEHoward
Cancer experts have made two calls for action from US lawmakers this year: fix the ongoing cancer drug shortage, and increase funding for cancer research cnn.it/3PAP6AJ




























